Table V.
Univariate analysis and multivariate analysis of prognostic factors in gastric cancer for overall survival.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | HR | P-value | 95% CI | HR | P-value | 95% CI |
| TCGA molecular subtype | 1.070 | 0.600 | 0.832–1.376 | |||
| EBV+ vs. MSI vs. GS vs. CIN | ||||||
| ACRG molecular subtype | 1.381 | 0.045 | 1.007–1.894 | 1.514 | 0.010 | 1.106–2.073 |
| MSI vs. MSS/EMT vs. MSS/TP53+ vs. MSS/TP53− | ||||||
| Sex | 1.267 | 0.512 | 0.626–2.564 | |||
| Male vs. Female | ||||||
| Age (years) | 1.142 | 0.688 | 0.598–2.179 | |||
| ≤60 vs. >60 | ||||||
| Tumor location | 1.417 | 0.290 | 0.743–2.705 | |||
| EGJ vs. Distal stomach | ||||||
| Lauren classification | 4.424 | 0.001 | 1.884–10.388 | 3.321 | 0.011 | 1.311–8.414 |
| Intestinal vs. Diffuse vs. Mixed | ||||||
| Adjuvant therapy | 2.373 | 0.013 | 1.204–4.676 | 2.002 | 0.068 | 0.950–4.219 |
| XELOX vs. SOX | ||||||
HR, hazard ratio; CI, confidence interval; TCGA, The Cancer Genome Atlas Consortium; EBV, Epstein-Barr virus; MSI, microsatellite instability; GS, gene stable; CIN, chromosome instability; ACRG, Asian Cancer Research Group; MSI, microsatellite instability; MSS microsatellite stable; EMT, epithelial-mesenchymal transition; TP53, tumor protein 53; EGJ, gastro-esophageal junction; XELOX, capecitabine combined with oxaliplatin; SOX, S1 combined with oxaliplatin.